Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Jul 30, 2026 | $1.62 | +153.1% | $12.97B | +5.7% | $1.60 |
| Q1 FY26ended Mar 31, 2026 | Apr 30, 2026 | $1.31 | +9.2% | $11.49B | +2.6% | $1.44 |
| Q4 FY25ended Dec 31, 2025 | — | $0.53 | +1225.0% | $12.50B | +1.3% | — |
| Q3 FY25ended Sep 30, 2025 | — | $1.08 | +80.0% | $12.22B | +2.8% | — |
| Q2 FY25ended Jun 30, 2025 | — | $0.64 | −22.9% | $12.27B | +0.6% | — |
| Q1 FY25ended Mar 31, 2025 | — | $1.20 | — | $11.20B | −5.6% | — |
| Q4 FY24ended Dec 31, 2024 | — | $0.04 | −95.4% | $12.34B | +7.5% | — |
| Q3 FY24ended Sep 30, 2024 | — | $0.60 | −35.5% | $11.89B | +8.4% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Bristol-Myers Squibb shares, not any token. As of Jul 30, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.83 | — | $12.20B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | −$5.89 | — | $11.87B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $0.87 | — | $11.48B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.93 | — | $10.97B | — | — |